adherent participants who received ET reported higher abstinence (60.5% and 44.2%) vs ST (44.7% and 27.7%), but differences in quit rates between arms were not significant for nonadherent participants (ET: 9.7% and 4.8%; ST: 12.7% and 10.9%). There were no significant differences between treatment arms on side effects, adverse and serious adverse events, and rates of high blood pressure (P's > 0.05).
The Surgeon General concluded that continued smoking by cancer patients is causally associated with all-cause and cancer-specific mortality. 1 Unfortunately, upwards of 50% of cancer patients who smoked prior to their diagnosis, continue to do so. 2 Consequently, leading cancer research and advocacy organizations have called for the improved treatment of tobacco use in the oncologic setting. 3 Given the remarkable improvements in cancer care, leading to 14 million current cancer survivors, 4 demonstrating the safety and efficacy of treatments for tobacco dependence in this population is a priority.
Few trials have evaluated smoking cessation interventions for cancer patients, which may contribute to the low rate of clinician treatment of patient tobacco use. 5 Smoking cessation interventions for cancer patients may be successful if population-specific cessation barriers are targeted. First, continuing to smoke after a cancer diagnosis centrally linked to tobacco is a hallmark of tobacco dependence. 6 While 35% to 54% of the general population of smokers report smoking their first cigarette within 30 minutes after waking, 7, 8 a measure of tobacco dependence, 9 this rate among cancer patients is 69% to 81%. [10] [11] [12] [13] Second, smoking cessation interventions for cancer patients may need to address the psychological distress 6, 14 and cognitive impairment [15] [16] [17] that often accompanies diagnosis and medical treatment and trigger smoking relapse. Lastly, smoking cessation treatments for cancer patients may need to consider the protracted time line for smoking relapse among cancer patients. 14 In the general population of smokers, the majority of smokers who achieve abstinence and relapse do so within 1 to 2 weeks. 18 Studies with cancer patients show that the majority of relapse to smoking occurs 2 to 6 months following initial abstinence. 19 Extended use varenicline 20 could be well suited for cancer patients who smoke. Varenicline mitigates the adverse psychological effects and withdrawal-related cognitive impairment associated with quitting smoking. 21, 22 We have shown in the general population that extending the use of transdermal nicotine to 24 weeks increases quit rates, vs 8 weeks, and significantly reduces the probability of a smoking lapse and increases the likelihood that smokers recover to abstinence. 23 While population and medication differences are important, extended duration varenicline may address cessation barriers among cancer patients.
A pilot study and an initial report describing 12-week open-label outcomes from this trial indicated that varenicline might be safe and efficacious for cancer patients. 24, 25 However, no study-with cancer patients or in the general population-has examined the efficacy and safety of extended varenicline treatment. This trial was designed to address this gap and determine if extended-use varenicline should be considered for treating tobacco use among cancer patients.
| METHODS
This placebo-controlled trial (NCT01756885) randomized participants to 12 weeks of varenicline followed by 12 weeks of placebo (standard Pill and counseling adherence was tracked. Counseling adherence was defined as completing greater than or equal to five per seven sessions (71%). The time line follow-back (TLFB) method 31 and collection of used blister packs tracked pill adherence. 29 A pill adherence measure represented the proportion of total dose taken over the 24 weeks (adherence: greater than or equal to 80% of 333 pills prescribed). We also collected a blood sample at week 4 among Penn participants who agreed to provide a blood sample and attended this session (N = 76) to determine varenicline plasma levels. 32 Smoking was assessed using TLFB and breath CO. 23 The primary outcomes were 7-day point prevalence abstinence at weeks 24 and 52 and a CO less than 10 ppm. 33, 34 Continuous abstinence (with CO) from weeks 9 to 24 and 9 to 52 were secondary outcomes consistent with past varenicline trials. 35 We examined time to relapse (in days) from the quit day (week 1) until a relapse (seven consecutive days of self-reported smoking) and smoking lapse and recovery 36 ; a smoking lapse was defined as any day between the quit date and the week 24 and 52 assessments on which participants smoked (even a puff); recovery was defined as any 24-hour period of self-reported abstinence postlapse. The analyses focused on treatment arm effects on time to transition between smoking and abstinent days. 23 We used intent-to-treat (ITT), meaning that participants lost to follow-up or failing to provide CO were considered smokers.
| ANALYSIS
The sample was characterized in terms of demographic, smoking, and disease characteristics. Variables listed in Table 1 (and clinical site) that differed between treatment arms (P < 0.05) were covariates in the analyses. Pill (self-report and varenicline levels) and counseling session adherence were characterized and compared across treatment arms.
To examine treatment arm effects on smoking cessation outcomes at weeks 24 and 52, we used logistic regression. For time to relapse, we used linear regression. Multivariate time-to-event models determined whether treatment arm predicted transitions from abstinence to lapse and from lapse to recovery. 23 Participants lost to follow-up on TLFB (for time-to-event analyses) were censored at that time Table 1 
| SAMPLE CHARACTERISTICS
Number of high blood pressure recordings 8 7 15 week 52, the interaction of treatment and adherence was not significant (OR = 2.16; 95% CI, 0.89-5.24; P = 0.09). There were no significant treatment effects on risk for relapse, lapse, or recovery (P's > 0.05).
| VARENICLINE SAFETY
Assessment of the change in mean side effect severity and the total frequency of side effects from week 0 (pretreatment), to weeks 4, 12, 18, and 24 showed no significant time X treatment effects (P's > 0.05). Likewise, there were no significant differences between treatments in the number of participants who reported AEs or SAEs between weeks 0 and 24 (P's > 0.05) or in the frequency of hypertension assessed at weeks 0, 12, and 24 (P's > 0.05; Table 2 ).
| CONCLUSIONS
We tested whether providing cancer patients interested in quitting smoking with 24 weeks of varenicline improved cessation rates vs 12 weeks of varenicline and was safe. Contrary to our hypothesis, the quit rates at weeks 24 and 52 were similar between the treatments. When considering varenicline adherence, however, ET yielded higher week 24 quit rates, vs ST. Further, there was no indication that ET varenicline was unsafe, vs ST.
Price et al 25 and Park et al 24 showed that 12 weeks of varenicline yields end-of-treatment quit rates for cancer patients that converge
with the general population of smokers using varenicline. However, factors unique to cancer patients (eg, high rates of emotional distress, 38 which can trigger smoking, and a protracted time line for relapse) suggest that ET varenicline might be required to ensure long-term smoking cessation success. Contrary to our hypothesis, ET for 24 weeks did not affect weeks 24 and 52 quit rates. One potential explanation for this result is that participants in the ST arm continued to receive smoking cessation counseling after week 12 (69% completed greater than or equal to five sessions); this was necessary to maintain the medication blind. The continued counseling could have prevented smoking relapse among participants in ST. Indeed, in post hoc analyses, the rate at which the weeks 14 and 18 sessions were completed was strongly associated with a greater likelihood for cessation at weeks 24 and 52 (P's < 0.05). The week 24 quit rates for both arms resemble the week 24 quit rates following only 12 weeks of varenicline treatment provided to the general population of smokers (ie, 34%-35%). 35 The week 24 quit rates are also substantially higher than a previous smoking cessation trial with cancer patients that provided behavioral counseling and bupropion. 11 However, it should be noted that the week 52 quit rates overall (approximately 16%)
were considerably lower than we have seen in the general population (eg, 24%). 35 Thus, while ET varenicline did not increase weeks 24 and 52 quit rates vs 12 weeks, ET through either medication or counseling may limit relapse, yield quit rates at week 24 that resemble those found among smokers in the general population, and yield higher quit rates seen in previous studies with cancer patients. Even so, the low week 52 quit rates indicate the need for additional intervention to reduce long-term relapse.
Second, based on pill count, less than 50% of the sample were adherent to varenicline, and level of varenicline adherence was associated with quit rates and interacted with treatment to affect quit rates at week 24. These results converge with a growing literature that highlights the importance of adherence in determining varenicline efficacy 37 and continues to underscore the need for interventions designed to address medication adherence within tobacco use treatment programs. We have shown previously that greater varenicline adherence among cancer patients may be associated with reductions in depressed mood and perceived satisfaction from smoking and an increase in the toxic effects of smoking, while cognition, craving, and side effects may also be important. 27 These results can guide the development and evaluation of interventions targeting varenicline adherence to improve cessation in this population. 
| Limitations
This study should be considered in the context of limitations. First, the ITT sample represents only 27% of the screened sample, diminishing the generalizability of the results. Trials with clinical populations experiencing physical and psychiatric comorbidities are challenging to implement given the need to control for potential extraneous variables and patient demands. However, once patients were enrolled, the majority completed counseling and remained in the program.
Second, compared with many varenicline trials conducted in the general population, 35 the present sample was small, and statistical power was diminished, which may underlie null effects; given the challenges of recruiting this clinical population, we did not meet our accrual goal of 374. However, this is one of the largest smoking cessation trials conducted with cancer patients. Lastly, adherence to varenicline was low, even vs the general population where it is typically 50% to 60%. 39, 40 With more than half the sample taking less than 80% of the prescribed medication, the therapeutic effect of varenicline was limited, which may have diminished long-term cessation. The complexity and intensity of ongoing medical care for patients may have posed particular challenges for treatment engagement and future studies are needed to develop and test novel approaches for increasing treatment adherence.
| Implications
Nevertheless, this study enhances our understanding of tobacco cessation treatment for cancer patients and has implications for the broader population. This is only the second study to examine the use of varenicline for cancer patients and shows that 12 or 24 weeks of treatment, when combined with counseling across 24 weeks, can help approximately one third of patients quit smoking without compromising safety. Further, this is the first study-with any population of smokers-to evaluate, using a placebo-controlled design, the benefits of ET varenicline and the results underscore the importance of medication adherence in maximizing the benefit of ET. Future studies are needed to identify effective methods to increase treatment adherence and improve long-term smoking cessation rates to help cancer patients benefit from smoking cessation treatment and enhance their prognosis.
